Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?

Milton Packer

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in the treatment of heart failure; yet only a minority (i.e., 30% to 40%) of eligible patients are being treated with these drugs, and even among treated patients, the doses used in clinical practice are substantially lower than those used in the clinical trials that established the efficacy and safety of these agents. The preference for low doses is based on the belief that low and high doses exert similar benefits but that high doses produce more side effects. Yet, most studies indicate that large doses of ACE inhibitors produce greater hemodynamic and clinical effects than small doses, with no additional toxicity. However, it is uncertain whether the survival effects of these drugs are also related to dose. To address this question, a large multinational, double-blind clinical trial (Assessment of Treatment With Lisinopril and Survival [ATLAS]) was launched to compare the effects of low and high doses of the ACE inhibitor lisinopril on the survival of patients with heart failure. If the study demonstrates that large doses are needed to produce optimal effects on mortality, then the low dose strategies that are now widely used in clinical practice may be inadvertently nullifying the enormous potential benefits that ACE inhibitors might otherwise have on public health.

Original languageEnglish (US)
Pages (from-to)1323-1327
Number of pages5
JournalJournal of the American College of Cardiology
Volume28
Issue number5
DOIs
StatePublished - Nov 1 1996

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Lisinopril
Survival
Clinical Trials
Treatment Failure
Pharmaceutical Preparations
Public Health
Hemodynamics
Safety
Mortality
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? / Packer, Milton.

In: Journal of the American College of Cardiology, Vol. 28, No. 5, 01.11.1996, p. 1323-1327.

Research output: Contribution to journalArticle

@article{0fcfed8e49a74648806f47869b19b740,
title = "Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?",
abstract = "Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in the treatment of heart failure; yet only a minority (i.e., 30{\%} to 40{\%}) of eligible patients are being treated with these drugs, and even among treated patients, the doses used in clinical practice are substantially lower than those used in the clinical trials that established the efficacy and safety of these agents. The preference for low doses is based on the belief that low and high doses exert similar benefits but that high doses produce more side effects. Yet, most studies indicate that large doses of ACE inhibitors produce greater hemodynamic and clinical effects than small doses, with no additional toxicity. However, it is uncertain whether the survival effects of these drugs are also related to dose. To address this question, a large multinational, double-blind clinical trial (Assessment of Treatment With Lisinopril and Survival [ATLAS]) was launched to compare the effects of low and high doses of the ACE inhibitor lisinopril on the survival of patients with heart failure. If the study demonstrates that large doses are needed to produce optimal effects on mortality, then the low dose strategies that are now widely used in clinical practice may be inadvertently nullifying the enormous potential benefits that ACE inhibitors might otherwise have on public health.",
author = "Milton Packer",
year = "1996",
month = "11",
day = "1",
doi = "10.1016/S0735-1097(96)00301-4",
language = "English (US)",
volume = "28",
pages = "1323--1327",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?

AU - Packer, Milton

PY - 1996/11/1

Y1 - 1996/11/1

N2 - Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in the treatment of heart failure; yet only a minority (i.e., 30% to 40%) of eligible patients are being treated with these drugs, and even among treated patients, the doses used in clinical practice are substantially lower than those used in the clinical trials that established the efficacy and safety of these agents. The preference for low doses is based on the belief that low and high doses exert similar benefits but that high doses produce more side effects. Yet, most studies indicate that large doses of ACE inhibitors produce greater hemodynamic and clinical effects than small doses, with no additional toxicity. However, it is uncertain whether the survival effects of these drugs are also related to dose. To address this question, a large multinational, double-blind clinical trial (Assessment of Treatment With Lisinopril and Survival [ATLAS]) was launched to compare the effects of low and high doses of the ACE inhibitor lisinopril on the survival of patients with heart failure. If the study demonstrates that large doses are needed to produce optimal effects on mortality, then the low dose strategies that are now widely used in clinical practice may be inadvertently nullifying the enormous potential benefits that ACE inhibitors might otherwise have on public health.

AB - Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in the treatment of heart failure; yet only a minority (i.e., 30% to 40%) of eligible patients are being treated with these drugs, and even among treated patients, the doses used in clinical practice are substantially lower than those used in the clinical trials that established the efficacy and safety of these agents. The preference for low doses is based on the belief that low and high doses exert similar benefits but that high doses produce more side effects. Yet, most studies indicate that large doses of ACE inhibitors produce greater hemodynamic and clinical effects than small doses, with no additional toxicity. However, it is uncertain whether the survival effects of these drugs are also related to dose. To address this question, a large multinational, double-blind clinical trial (Assessment of Treatment With Lisinopril and Survival [ATLAS]) was launched to compare the effects of low and high doses of the ACE inhibitor lisinopril on the survival of patients with heart failure. If the study demonstrates that large doses are needed to produce optimal effects on mortality, then the low dose strategies that are now widely used in clinical practice may be inadvertently nullifying the enormous potential benefits that ACE inhibitors might otherwise have on public health.

UR - http://www.scopus.com/inward/record.url?scp=0030298330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030298330&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(96)00301-4

DO - 10.1016/S0735-1097(96)00301-4

M3 - Article

C2 - 8890833

AN - SCOPUS:0030298330

VL - 28

SP - 1323

EP - 1327

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -